The U.S. Food and Drug Administration (FDA) has initiated a priority review of Merck’s supplemental Biologics License Application (sBLA), according to a recent announcement made by Merck on 20th September.
The application specifically involves the use of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy that Merck is aiming to use as part of an innovative treatment plan for newly diagnosed high-risk cervical cancer patients. This treatment regimen would also incorporate both external beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy.
This marks a significant step forward in the evolving landscape of cervical cancer treatment, as this therapy could, if approved, offer an alternative to patients with locally advanced cervical cancer, a category that often presents more risk factors and complications in treatment.
However, it is important to note that the FDA’s Priority Review action does not ensure final regulatory approval. It merely speeds up the process of reviewing the treatment, which could otherwise take months or even years. This priority designation is often assigned to new therapies that, if approved, would greatly improve the safety or effectiveness of treating a serious or potentially life-threatening condition.
While the outcome of the priority review is yet to be determined, the initiation is certainly a promising step for Merck and for patients affected by this type of cancer. It offers further evidence of the medical field’s continuing efforts to harness the potential of biologics and pharmaceuticals in more effective cancer therapies.